We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.
- Authors
Tao, Tao; Wu, Peihong; Wang, Yuying; Liu, Wei
- Abstract
Background: Impaired insulin activity in women with polycystic ovary syndrome might differ from that seen in type 2 diabetes mellitus without polycystic ovary syndrome. This study was designed to compare the effects of treatment with metformin, saxagliptin, and their combination in newly diagnosed women with type 2 diabetes mellitus and polycystic ovary syndrome in China. Methods: A total of 75 newly diagnosed patients from Shanghai, China with type 2 diabetes mellitus and polycystic ovary syndrome were included in this randomized, parallel, open-label study. All patients received treatment for 24 weeks with metformin, saxagliptin, or their combination. Patients were allocated to one of three treatment groups by a computer-generated code that facilitated equal patient distribution of 25 patients per group. The primary outcome was a change in glycemic control and β-cell function. Results: A total of 63 patients completed the study (<italic>n</italic> = 21, for each group). The reduction in hemoglobin A1c was significant in the combination group, compared to the monotherapy groups (saxagliptin vs. combination treatment vs. metformin: − 1.1 vs. -1.3 vs. -1.1%, <italic>P</italic> = 0.016), whereas it was comparable between the metformin and saxagliptin groups (<italic>P</italic> > 0.05). Saxagliptin, metformin, and the combination treatment significantly reduced the homeostasis model assessment- insulin resistance index and increased the deposition index (<italic>P</italic> < 0.01 for all). However, no significant change was observed in the homeostasis model assessment- β-cell function among the metformin and combination groups, and no significant changes were observed in the insulinogenic index among all three groups (<italic>P</italic> > 0.05 for all). In addition, saxagliptin and metformin treatments significantly reduced body mass index and high-sensitivity C-reactive protein levels (<italic>P</italic> < 0.01 for both). Conclusions: Saxagliptin and metformin were comparably effective in regulating weight loss, glycemic control, and β-cell function, improving lipid profiles, and reducing inflammation in newly diagnosed type 2 diabetes mellitus patients with polycystic ovary syndrome. Trial registration: ChiCTR-IPR-17011120 (retrospectively registered on 2017–04-12).
- Subjects
CHINA; ISLANDS of Langerhans; HYPOGLYCEMIC agents; METFORMIN; AGE factors in disease; C-reactive protein; COMBINATION drug therapy; COMPARATIVE studies; PEOPLE with diabetes; GLYCOSYLATED hemoglobin; INFLAMMATION; LIPIDS; TYPE 2 diabetes; POLYCYSTIC ovary syndrome; WEIGHT loss; BODY mass index; RANDOMIZED controlled trials; TREATMENT effectiveness; GLYCEMIC control; PHYSIOLOGY
- Publication
BMC Endocrine Disorders, 2018, Vol 18, p1
- ISSN
1472-6823
- Publication type
Article
- DOI
10.1186/s12902-018-0243-5